Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.

TSX:TH - Post by User

Theratechnologies Inc > Share price will not move up

<< Previous

Bullboard Posts

Next >>

Comment by SPCEO1on Nov 09, 2022 10:58pm

115 Views

Post# 35087308

RE:RE:RE:RE:RE:RE:RE:Share price will not move up

As best I could tell, my efforts with the weekly report card to influence management in 2021, during a raging bubble, to join the party. Perhaps someone else would have more success but we are in a bear market now, so the benefit of a change in approach now would likely be less impactful. Still, it couldn't hurt to take a different approach as the current approach isn't working and management must be starting to fear a bit for their job security. This close to getting cancer results that will define the future of the company, however, I wouldn't expect much to change. Maybe after those results things will change but not likely before.